{
    "id": "2o3k6fannfkw3pb2uyh7beck76wtfbmv",
    "title": "Tiresias: Predicting Drug-Drug Interactions Through Large-Scale Similarity-Based Link Prediction",
    "info": {
        "author": [
            "Achille Fokoue, IBM Research"
        ],
        "published": "July 28, 2016",
        "recorded": "May 2016",
        "category": [
            "Top->Computer Science->Big Data",
            "Top->Computer Science->Semantic Web"
        ]
    },
    "url": "http://videolectures.net/eswc2016_fokoue_link_prediction/",
    "segmentation": [
        [
            "So briefly, to motivate and."
        ],
        [
            "Martin said that problem adverse drug reactions in general poses serious challenge to the health care system we are talking about a significant human cost in the US on in the US every year we have over 2 million people who suffer serious adverse drug reactions and that leads to close to 100,000 deaths just in the US.",
            "So in addition to that, human cars is also significant financial costs associated with these adverse drug reaction.",
            "Again, an estimation of close to 100 billion dollar is spent every year in the US just to mitigate the consequences of these adverse drug reactions.",
            "And this is for this more than what we spend on card.",
            "You know, cardiovascular or diabetic care.",
            "An important problem is that most of these adverse drug reactions are not easily detected during clinical trials, and this for many reasons in particular due to the.",
            "Red toxicity of some drugs, but also if you look at the case of drug interaction, there are so many combinations that it's very expensive actually to to test them in a systematic way through clinical trial in the US for example, they are up to 2000.",
            "They are close to 2000 approved drugs, right?",
            "So if you think of designing clinical trial to test the safety of all the combinations you talking about close to 2 million clinical trial that need to do.",
            "Clearly that would be too expensive and before a new drug comes in the market.",
            "If you want to test whether that new drug is safe when used in combination with any of the 2000 approved drugs, again, you're talking about nearly 2000 clinical trials, and again too expensive to to perform in practice.",
            "So the only you know scalable way to explore that large space of unknown drug drug reaction is really through the kind of in silicone experiment that we did.",
            "The less important fact about the importance of drug drug interaction in particular is that in the US it is estimated that somewhere between 3 and 5% of in hospital medical errors are due to this anthracene drug interactions."
        ],
        [
            "So this is clearly something very important."
        ],
        [
            "Now our work really is in line in is in line with the growing interesting line of work and trying to use similarity based.",
            "You know approach to a make this prediction this similarity based approaches are really inspired from content content based similarity.",
            "I mean content based recommender system.",
            "So in this content based recommender system, the basic idea here that we borrow is to predict you know the existence of a drug drug interaction.",
            "Based on the comparison of our candidate pair against a set of non interacting drugs, let me give you a concrete example.",
            "Imagine that we have two drugs here, Salsalate, an strep to missing an.",
            "We want to check whether these two drugs might interact.",
            "So one way to do that is to look at a large set of known drug drug interactions and hope to find in that last set a pair or many pairs that are very similar to our candidate pair.",
            "So if we do that, we can actually find one pair here.",
            "Aspirin and arixtra missing and comparing the first drug using the chemical structure, we actually realize that salsalate an aspirin are very closed based on the chemical structure.",
            "The similarity score that we get here is 0.9.",
            "So in general, signature measures are very important component of our approach, right?",
            "Personality measure is really a function that takes 2 drugs and return.",
            "A number between zero and one, where 0 means you know know much at all, and one means perfect alignment.",
            "So here is 0.1 is a fairly high score.",
            "Likewise we compare the two second drugs and this time we use a different similarity measure to compare them.",
            "We compare them based on the mechanism of action.",
            "We get that information from a source code and the FRT, where we learn that you know the first drug and the second drugs are both protein synthesis.",
            "Inhibitor so based on the mechanism of action, they actually exactly the same, so we get the the higher similarity score.",
            "The final step is to actually combine these two score into a unique score using harmonic mean and we get combined score of 0.5.",
            "Sorry, Zero point 95 so that higher score is clearly a piece of evidence in favor of the interaction between salsalate and streptomycin.",
            "Because we are able to find unknown interacting pair that is very similar to it.",
            "Now the real question now is, how do you combine all these different pieces of evidence that you get from all this similarity matrix?",
            "Because in reality we don't have just two similarity metrics presented here.",
            "In the paper we describe 13 similarity metrics in our current system.",
            "We actually have up to 20 similarity metrics.",
            "So the question now is how do you combine result you get from all the combination of similarity metrics.",
            "So here will be 13 squared over.",
            "All the known and drug drug interaction pair which is in the paper close to 2020.",
            "Three 12,000 known interacting pairs."
        ],
        [
            "Soon.",
            "Our work extends that basic framework on drug drug similarity prediction based on similarity metrics.",
            "We address some of the limitations and shortcomings that were mostly overlooked by prior work.",
            "The first one is that we focus more on the important important use case of newly introduced drug, so these are really drug for which we don't have any known interacting drugs, right?",
            "So prior system prior work are either fundamentally unable to make prediction for newly developed drugs, and this is not actually a new.",
            "This is a standard problem that we have with content based recommender system.",
            "This is standard bootstrapping problem.",
            "Very good illustration of that is from the work from Villar, So what they did is to make the prediction based on the ability to 1st for each drug they build what they call.",
            "Interaction profile for the drug interaction profile for a drug is conceptually a set of other drugs that are known to interact with your drug of interest right, and they make the prediction based on comparing this interaction.",
            "Profiles for drugs.",
            "Obviously the problem when you have a newly developed drug is that his interaction profile is empty.",
            "You don't know anything about it.",
            "Essentially don't know which other drugs interact with.",
            "You haven't done any clinical trial at that point, and so I guess not be used yet, so that's a fundamental limitation for.",
            "A lot of paperwork or their work actually able to, you know, to make in principle they are able to deal with the problem of the scenario of newly developed drug.",
            "But in practice when you look at the evaluation, typically they are not evaluated for that scenario.",
            "Scenario of newly introduced throughout what they do in the evaluation.",
            "In the standard 10 fold cross validation is that they hide pair of drugs from the training data, which is good, but.",
            "But it's not enough, because a testing there have been new pair of drugs that were not seen at training.",
            "But most of this pair of drugs we have two drugs.",
            "There were already seen at training, so they are clearly not simulating the case of a newly developed drugs, so that our focus really is to deal with this important case of newly developed drugs.",
            "Another important limitation of prior work is that they made the assumption that the distribution of drug drug interaction is fairly balanced.",
            "They assume a priori 50%.",
            "You know balance between positive and negative example.",
            "An in reality and we are sure that we showed that in the paper.",
            "In reality as a fraction of drug interaction in the set of all drug pair is much lower than 50%.",
            "And in the paper we estimated to be somewhere between 10 and 30%, and that's actually has important ramifications in terms of performance.",
            "When I would show you the evaluation that we did, you see that.",
            "Existing systems instead of the art performed poorly on this skewed distribution of drug interactions.",
            "Now."
        ],
        [
            "Another important issue in prior work is the question of what's right and metrics to use to measure the quality of our drug drug interaction predictions.",
            "Right prayer work for the most part, rely on the area under our see curves to assess the quality of the prediction, but it it has been well documented that this is not a great metric when it comes to dealing with skewed distribution.",
            "In particular, in Davis work, they actually produce these nice at two graphs which show 2 algorithm and when you look at the performance of these two algorithm using our see curves you get something like that which is very close to perfection really is close to perfect our see.",
            "But the same algorithm when using different metrics which are more appropriate for skewed distribution really produce poor or mediocre result when using recalling.",
            "Precision using precision recall curves.",
            "So the lesson here is that our C is probably fine if you have a fairly balanced distribution of positive and negative example when one, but when you have a very skewed distribution, piracy is not a good indicator of the quality of your prediction.",
            "We also see that in our own evaluation of the state of the art system when you evaluate them using our see, you actually get fairly excellent result.",
            "You know you get our see close 2.0 point.",
            "90 at 294, which is close to perfection, but the same system evaluated on skewed distribution, produce average or mediocre F score or area under precision recall curve.",
            "So the important thing here is to use the appropriate metrics for skewed distribution and in our world we use F score precision, recall an area under precision recall."
        ],
        [
            "Another important departure from the prior work is that most of the prior work, an similarity based drug drug interactions, use limited number of data source to build their similarity measure and for the prediction.",
            "In our case, we exploit data originating from a variety of data sources to build multiple similarity measures.",
            "So in addition to the standard, you know data integration issue that you have when you put together much per source like that things like you know having to deal with you know, you know entity resolution, entity linking.",
            "There's another important problem here which comes to which comes from the fact that.",
            "Different data source will have only partial information about the subset of your drugs.",
            "As a result, similar to metrics that you build from these sources will have different degree of incompleteness and this is something very important because the machine learning that we use at the end to integrate all of our piece of evidence need to understand the difference between.",
            "You know having a low similarity matrix because we were not able to find.",
            "Or is information about the two drugs care about or having a loose enlarging metrics because you know the two drugs are really dissimilar, so we really need to introduce new type of feature machine learning feature to help the machine learner understand whether zalo zalo similarity score comes from partial information, incomplete information, or it's a real indication of the similarity between our two drugs.",
            "So that's why we introduced this important calibration feature that I will describe later on."
        ],
        [
            "Now let me give you a quick overview of how the approach works.",
            "So we start by collecting, analyzing, integrating, and curating information coming from a variety of sources including drug Bank, City, DUM, LS, Uniprot and other sources.",
            "At the end of that process, we conceptually have a knowledge graph, and from it we build an two types of tables.",
            "These blue tables.",
            "Here, each of these blue tables are conceptually similarity metrics, right?",
            "The first one is actually the chemical structure similarity metrics and you can see the two drugs that we had before set select an aspirin with the similarity metric of 0.9 based on the chemical structure.",
            "So we built in the paper.",
            "We describe 13 sets in larger metrics, so we have.",
            "13 blue table in the current system we actually added more.",
            "Now we're close to 20 signature metrics.",
            "In addition to these similarity metrics that we built from all these sources, we also extract from a subset of these sources information about known interacting pair of drugs.",
            "Video here.",
            "The next step is to.",
            "Bill for each candidate drugs here.",
            "For example, Salsalate and wife ring to build a set of feature vector and this feature vector and I'll describe that in more detail later on.",
            "It's really bill from information coming from this similarity matrix.",
            "Abit like what I showed you in the example right for each similar geometric for its enlarging metrics we will compare, you know, our candidate against drugs that are already known to interact."
        ],
        [
            "There's a number of similarity metrics that we have is much higher than what other system had.",
            "As a result, we have a much larger number of features and that poses a potential problem of overfitting.",
            "For machine learning, approach is very important to address that using L2 regularization.",
            "So instead of building 1 model we actually build.",
            "Up to close to 8 models with different regularization parameter through validation cross validation, we get the best regression regularization factor.",
            "We also get the best threshold right and at the end we can use that model to make our predictions.",
            "So that's kind of the standard pipeline that we use, and you could ask why logistic regression.",
            "We actually we actually tested many order and models.",
            "You just turned out that logistic regression is the one that produced the best performance in terms of quality of our predictions."
        ],
        [
            "Now I'm going to describe briefly some of the measures that we used to compare drugs.",
            "The first one is the chemical putting into a term incorrect term profile based in large measure.",
            "So what we call CPI profile for drug, it's essentially a vector that measure how well your drugs had binds against about 600 human proteins, right?",
            "And we compare these drugs based on how well these you know.",
            "We compared to drugs based on the cosine, you know.",
            "So mean, center cosine of the CPI profile vector.",
            "It's essentially you're kind of computing the Pearson correlation between the two vectors.",
            "Another important similarity measure is the mechanism of action based in large measure, you saw that in the example we get for each drug we get information about its mechanism of action from a source which is part of your melesko NDF RT and conceptually for each drug we then have a vector of all its mechanism of action.",
            "It's important to discount frequently occurring mechanism of action mechanism.",
            "Action data just too generic to popular.",
            "We use the IDF inverse document frequency to you know to discount them.",
            "So and at the end we we perform the IDF adjusted cosine similarity matrix as our signature value.",
            "So same approach is used for pathways so we get from another source called CTD for each drug we have the list of biological pathways in which the drug is involved or at least bearish pathway.",
            "That's a drug.",
            "May I disrupt or.",
            "Interfere with right?",
            "And then you compare this drug based on on on these basket pathways vectors and again using IDF adjust the cosine similarity measures.",
            "We have many more similarity measure.",
            "I won't go into more detail just to say that another interesting one is to compare drugs based on the similarity of the of the physiological effect that they have in the body.",
            "Another interesting one is comparing comparison of drugs based and then known side effect and you can have more."
        ],
        [
            "Detail in the paper.",
            "Now let me briefly describe how we build.",
            "Once we have all these similarity measure measures 13 in the paper 20.",
            "Currently, how we go from there?",
            "How we go from there to actually building?",
            "You know, the set of features.",
            "So, given a drug you know probably look like that we have our set of non drug similarity.",
            "So we pick two similarity S1 and S2.",
            "So we we compare our our candidate against each non drugs and obviously we still use how many means to combine the two score.",
            "Here we had zero, 44 had 0.80 zero point 6 at the end.",
            "The first feature that we use is the maximum value that we get here is 0.8 that's our first feature.",
            "This actually what externally this standard feature using most system.",
            "It gives you an idea of it tells you that there is a drug that is very similar to yours.",
            "Your candidate right, but it just provides a limited view of all that distribution.",
            "So really what we want to do is add additional calibration feature to really summarize the distribution.",
            "So we use.",
            "In addition we use mean standard deviation and this call for that Max value, which essentially tells us how far from the mean that Max value.",
            "He's so it tell us whether you know that maximum value that we have, it's really outlier or it's really close to the mean.",
            "The average I'm not going to go.",
            "Another important similarity measure that we use here is these calibration and metrics.",
            "So if you look at all the measure that we have now, they're actually comparing our candidate drugs against drugs that are known to interact.",
            "But it could be the fact that you found a pair of drugs that is very similar to.",
            "Are these drugs, but at the same time that pair of drawings also seem not to just all drugs, right?",
            "So it's very important to also have a metrics that tell us what the average you know similarity of your candidate against all drugs, whether or not they are known to interact, and that's what that last feature does.",
            "So at the end we end up with, you know, this number of features.",
            "That's why it's very important to to care about, you know, overfitting and regularization."
        ],
        [
            "So I'm not going to go in detail of how we make our you know how we find these lower bound for the drug drug interaction prevalence.",
            "But you can see the detail in the paper in a nutshell, we were able to estimate that in reality you know the proof, the fraction of drug drug interaction in the set of all drugs is somewhere between 10 and 30%."
        ],
        [
            "Now evaluation, we did two experiments to evaluate the quality of our prediction.",
            "The first is kind of a retrospective analysis where we try to see the extent to which our system is able to make correct prediction, but yet unknown prediction.",
            "So in order to do that, we run our system using only, you know, drugs, drugs, pair that were known as of 2011.",
            "So we were trying to simulate what could we have discovered if we had run our system in 2011.",
            "What is the fraction of new drug interaction that we could have a discover back in 2011?",
            "And the answer is that we can actually discover up to 28% drug interaction and we do a much better when we use the calibration feature that we introduce.",
            "So this gives us an idea about the coverage of our system, right?",
            "We still need to correct precision or you know, the first positive rate, right?",
            "So I."
        ],
        [
            "I'm running out of time, so we did the standard 10 fold cross validation experiment to measure our F score and but also the area under the curve and we.",
            "We evaluate how this matrix, if you know, evolved as we change the fraction of positive and negative example and what you can see from this curve is that is really important to actually consider relatively low performance.",
            "So in a nutshell, let me just summarize the result here so that curve that you see here the dotted black line.",
            "This is essentially the baseline that's the state of the art system really without using our our calibration feature and using a 5050%.",
            "Balance training data set.",
            "So what you can see is that is clearly underperformed our system when we use unbalanced data and when we use our collaboration features."
        ],
        [
            "And maybe you have one second without probably step here and ask for questions.",
            "And if I don't have enough question, maybe I can give you a demo quickly."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So briefly, to motivate and.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Martin said that problem adverse drug reactions in general poses serious challenge to the health care system we are talking about a significant human cost in the US on in the US every year we have over 2 million people who suffer serious adverse drug reactions and that leads to close to 100,000 deaths just in the US.",
                    "label": 1
                },
                {
                    "sent": "So in addition to that, human cars is also significant financial costs associated with these adverse drug reaction.",
                    "label": 0
                },
                {
                    "sent": "Again, an estimation of close to 100 billion dollar is spent every year in the US just to mitigate the consequences of these adverse drug reactions.",
                    "label": 0
                },
                {
                    "sent": "And this is for this more than what we spend on card.",
                    "label": 0
                },
                {
                    "sent": "You know, cardiovascular or diabetic care.",
                    "label": 1
                },
                {
                    "sent": "An important problem is that most of these adverse drug reactions are not easily detected during clinical trials, and this for many reasons in particular due to the.",
                    "label": 0
                },
                {
                    "sent": "Red toxicity of some drugs, but also if you look at the case of drug interaction, there are so many combinations that it's very expensive actually to to test them in a systematic way through clinical trial in the US for example, they are up to 2000.",
                    "label": 0
                },
                {
                    "sent": "They are close to 2000 approved drugs, right?",
                    "label": 0
                },
                {
                    "sent": "So if you think of designing clinical trial to test the safety of all the combinations you talking about close to 2 million clinical trial that need to do.",
                    "label": 0
                },
                {
                    "sent": "Clearly that would be too expensive and before a new drug comes in the market.",
                    "label": 0
                },
                {
                    "sent": "If you want to test whether that new drug is safe when used in combination with any of the 2000 approved drugs, again, you're talking about nearly 2000 clinical trials, and again too expensive to to perform in practice.",
                    "label": 0
                },
                {
                    "sent": "So the only you know scalable way to explore that large space of unknown drug drug reaction is really through the kind of in silicone experiment that we did.",
                    "label": 0
                },
                {
                    "sent": "The less important fact about the importance of drug drug interaction in particular is that in the US it is estimated that somewhere between 3 and 5% of in hospital medical errors are due to this anthracene drug interactions.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So this is clearly something very important.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now our work really is in line in is in line with the growing interesting line of work and trying to use similarity based.",
                    "label": 0
                },
                {
                    "sent": "You know approach to a make this prediction this similarity based approaches are really inspired from content content based similarity.",
                    "label": 0
                },
                {
                    "sent": "I mean content based recommender system.",
                    "label": 0
                },
                {
                    "sent": "So in this content based recommender system, the basic idea here that we borrow is to predict you know the existence of a drug drug interaction.",
                    "label": 1
                },
                {
                    "sent": "Based on the comparison of our candidate pair against a set of non interacting drugs, let me give you a concrete example.",
                    "label": 0
                },
                {
                    "sent": "Imagine that we have two drugs here, Salsalate, an strep to missing an.",
                    "label": 1
                },
                {
                    "sent": "We want to check whether these two drugs might interact.",
                    "label": 0
                },
                {
                    "sent": "So one way to do that is to look at a large set of known drug drug interactions and hope to find in that last set a pair or many pairs that are very similar to our candidate pair.",
                    "label": 0
                },
                {
                    "sent": "So if we do that, we can actually find one pair here.",
                    "label": 0
                },
                {
                    "sent": "Aspirin and arixtra missing and comparing the first drug using the chemical structure, we actually realize that salsalate an aspirin are very closed based on the chemical structure.",
                    "label": 0
                },
                {
                    "sent": "The similarity score that we get here is 0.9.",
                    "label": 0
                },
                {
                    "sent": "So in general, signature measures are very important component of our approach, right?",
                    "label": 0
                },
                {
                    "sent": "Personality measure is really a function that takes 2 drugs and return.",
                    "label": 0
                },
                {
                    "sent": "A number between zero and one, where 0 means you know know much at all, and one means perfect alignment.",
                    "label": 0
                },
                {
                    "sent": "So here is 0.1 is a fairly high score.",
                    "label": 0
                },
                {
                    "sent": "Likewise we compare the two second drugs and this time we use a different similarity measure to compare them.",
                    "label": 0
                },
                {
                    "sent": "We compare them based on the mechanism of action.",
                    "label": 1
                },
                {
                    "sent": "We get that information from a source code and the FRT, where we learn that you know the first drug and the second drugs are both protein synthesis.",
                    "label": 1
                },
                {
                    "sent": "Inhibitor so based on the mechanism of action, they actually exactly the same, so we get the the higher similarity score.",
                    "label": 0
                },
                {
                    "sent": "The final step is to actually combine these two score into a unique score using harmonic mean and we get combined score of 0.5.",
                    "label": 0
                },
                {
                    "sent": "Sorry, Zero point 95 so that higher score is clearly a piece of evidence in favor of the interaction between salsalate and streptomycin.",
                    "label": 0
                },
                {
                    "sent": "Because we are able to find unknown interacting pair that is very similar to it.",
                    "label": 0
                },
                {
                    "sent": "Now the real question now is, how do you combine all these different pieces of evidence that you get from all this similarity matrix?",
                    "label": 0
                },
                {
                    "sent": "Because in reality we don't have just two similarity metrics presented here.",
                    "label": 0
                },
                {
                    "sent": "In the paper we describe 13 similarity metrics in our current system.",
                    "label": 0
                },
                {
                    "sent": "We actually have up to 20 similarity metrics.",
                    "label": 0
                },
                {
                    "sent": "So the question now is how do you combine result you get from all the combination of similarity metrics.",
                    "label": 0
                },
                {
                    "sent": "So here will be 13 squared over.",
                    "label": 0
                },
                {
                    "sent": "All the known and drug drug interaction pair which is in the paper close to 2020.",
                    "label": 0
                },
                {
                    "sent": "Three 12,000 known interacting pairs.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Soon.",
                    "label": 0
                },
                {
                    "sent": "Our work extends that basic framework on drug drug similarity prediction based on similarity metrics.",
                    "label": 0
                },
                {
                    "sent": "We address some of the limitations and shortcomings that were mostly overlooked by prior work.",
                    "label": 0
                },
                {
                    "sent": "The first one is that we focus more on the important important use case of newly introduced drug, so these are really drug for which we don't have any known interacting drugs, right?",
                    "label": 0
                },
                {
                    "sent": "So prior system prior work are either fundamentally unable to make prediction for newly developed drugs, and this is not actually a new.",
                    "label": 1
                },
                {
                    "sent": "This is a standard problem that we have with content based recommender system.",
                    "label": 1
                },
                {
                    "sent": "This is standard bootstrapping problem.",
                    "label": 0
                },
                {
                    "sent": "Very good illustration of that is from the work from Villar, So what they did is to make the prediction based on the ability to 1st for each drug they build what they call.",
                    "label": 0
                },
                {
                    "sent": "Interaction profile for the drug interaction profile for a drug is conceptually a set of other drugs that are known to interact with your drug of interest right, and they make the prediction based on comparing this interaction.",
                    "label": 0
                },
                {
                    "sent": "Profiles for drugs.",
                    "label": 0
                },
                {
                    "sent": "Obviously the problem when you have a newly developed drug is that his interaction profile is empty.",
                    "label": 0
                },
                {
                    "sent": "You don't know anything about it.",
                    "label": 0
                },
                {
                    "sent": "Essentially don't know which other drugs interact with.",
                    "label": 0
                },
                {
                    "sent": "You haven't done any clinical trial at that point, and so I guess not be used yet, so that's a fundamental limitation for.",
                    "label": 0
                },
                {
                    "sent": "A lot of paperwork or their work actually able to, you know, to make in principle they are able to deal with the problem of the scenario of newly developed drug.",
                    "label": 0
                },
                {
                    "sent": "But in practice when you look at the evaluation, typically they are not evaluated for that scenario.",
                    "label": 0
                },
                {
                    "sent": "Scenario of newly introduced throughout what they do in the evaluation.",
                    "label": 0
                },
                {
                    "sent": "In the standard 10 fold cross validation is that they hide pair of drugs from the training data, which is good, but.",
                    "label": 0
                },
                {
                    "sent": "But it's not enough, because a testing there have been new pair of drugs that were not seen at training.",
                    "label": 0
                },
                {
                    "sent": "But most of this pair of drugs we have two drugs.",
                    "label": 1
                },
                {
                    "sent": "There were already seen at training, so they are clearly not simulating the case of a newly developed drugs, so that our focus really is to deal with this important case of newly developed drugs.",
                    "label": 1
                },
                {
                    "sent": "Another important limitation of prior work is that they made the assumption that the distribution of drug drug interaction is fairly balanced.",
                    "label": 1
                },
                {
                    "sent": "They assume a priori 50%.",
                    "label": 0
                },
                {
                    "sent": "You know balance between positive and negative example.",
                    "label": 0
                },
                {
                    "sent": "An in reality and we are sure that we showed that in the paper.",
                    "label": 0
                },
                {
                    "sent": "In reality as a fraction of drug interaction in the set of all drug pair is much lower than 50%.",
                    "label": 1
                },
                {
                    "sent": "And in the paper we estimated to be somewhere between 10 and 30%, and that's actually has important ramifications in terms of performance.",
                    "label": 0
                },
                {
                    "sent": "When I would show you the evaluation that we did, you see that.",
                    "label": 0
                },
                {
                    "sent": "Existing systems instead of the art performed poorly on this skewed distribution of drug interactions.",
                    "label": 0
                },
                {
                    "sent": "Now.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Another important issue in prior work is the question of what's right and metrics to use to measure the quality of our drug drug interaction predictions.",
                    "label": 0
                },
                {
                    "sent": "Right prayer work for the most part, rely on the area under our see curves to assess the quality of the prediction, but it it has been well documented that this is not a great metric when it comes to dealing with skewed distribution.",
                    "label": 0
                },
                {
                    "sent": "In particular, in Davis work, they actually produce these nice at two graphs which show 2 algorithm and when you look at the performance of these two algorithm using our see curves you get something like that which is very close to perfection really is close to perfect our see.",
                    "label": 0
                },
                {
                    "sent": "But the same algorithm when using different metrics which are more appropriate for skewed distribution really produce poor or mediocre result when using recalling.",
                    "label": 0
                },
                {
                    "sent": "Precision using precision recall curves.",
                    "label": 0
                },
                {
                    "sent": "So the lesson here is that our C is probably fine if you have a fairly balanced distribution of positive and negative example when one, but when you have a very skewed distribution, piracy is not a good indicator of the quality of your prediction.",
                    "label": 0
                },
                {
                    "sent": "We also see that in our own evaluation of the state of the art system when you evaluate them using our see, you actually get fairly excellent result.",
                    "label": 0
                },
                {
                    "sent": "You know you get our see close 2.0 point.",
                    "label": 0
                },
                {
                    "sent": "90 at 294, which is close to perfection, but the same system evaluated on skewed distribution, produce average or mediocre F score or area under precision recall curve.",
                    "label": 1
                },
                {
                    "sent": "So the important thing here is to use the appropriate metrics for skewed distribution and in our world we use F score precision, recall an area under precision recall.",
                    "label": 1
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Another important departure from the prior work is that most of the prior work, an similarity based drug drug interactions, use limited number of data source to build their similarity measure and for the prediction.",
                    "label": 1
                },
                {
                    "sent": "In our case, we exploit data originating from a variety of data sources to build multiple similarity measures.",
                    "label": 1
                },
                {
                    "sent": "So in addition to the standard, you know data integration issue that you have when you put together much per source like that things like you know having to deal with you know, you know entity resolution, entity linking.",
                    "label": 1
                },
                {
                    "sent": "There's another important problem here which comes to which comes from the fact that.",
                    "label": 0
                },
                {
                    "sent": "Different data source will have only partial information about the subset of your drugs.",
                    "label": 0
                },
                {
                    "sent": "As a result, similar to metrics that you build from these sources will have different degree of incompleteness and this is something very important because the machine learning that we use at the end to integrate all of our piece of evidence need to understand the difference between.",
                    "label": 1
                },
                {
                    "sent": "You know having a low similarity matrix because we were not able to find.",
                    "label": 0
                },
                {
                    "sent": "Or is information about the two drugs care about or having a loose enlarging metrics because you know the two drugs are really dissimilar, so we really need to introduce new type of feature machine learning feature to help the machine learner understand whether zalo zalo similarity score comes from partial information, incomplete information, or it's a real indication of the similarity between our two drugs.",
                    "label": 0
                },
                {
                    "sent": "So that's why we introduced this important calibration feature that I will describe later on.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Now let me give you a quick overview of how the approach works.",
                    "label": 0
                },
                {
                    "sent": "So we start by collecting, analyzing, integrating, and curating information coming from a variety of sources including drug Bank, City, DUM, LS, Uniprot and other sources.",
                    "label": 0
                },
                {
                    "sent": "At the end of that process, we conceptually have a knowledge graph, and from it we build an two types of tables.",
                    "label": 0
                },
                {
                    "sent": "These blue tables.",
                    "label": 0
                },
                {
                    "sent": "Here, each of these blue tables are conceptually similarity metrics, right?",
                    "label": 0
                },
                {
                    "sent": "The first one is actually the chemical structure similarity metrics and you can see the two drugs that we had before set select an aspirin with the similarity metric of 0.9 based on the chemical structure.",
                    "label": 0
                },
                {
                    "sent": "So we built in the paper.",
                    "label": 0
                },
                {
                    "sent": "We describe 13 sets in larger metrics, so we have.",
                    "label": 0
                },
                {
                    "sent": "13 blue table in the current system we actually added more.",
                    "label": 0
                },
                {
                    "sent": "Now we're close to 20 signature metrics.",
                    "label": 0
                },
                {
                    "sent": "In addition to these similarity metrics that we built from all these sources, we also extract from a subset of these sources information about known interacting pair of drugs.",
                    "label": 0
                },
                {
                    "sent": "Video here.",
                    "label": 0
                },
                {
                    "sent": "The next step is to.",
                    "label": 0
                },
                {
                    "sent": "Bill for each candidate drugs here.",
                    "label": 0
                },
                {
                    "sent": "For example, Salsalate and wife ring to build a set of feature vector and this feature vector and I'll describe that in more detail later on.",
                    "label": 0
                },
                {
                    "sent": "It's really bill from information coming from this similarity matrix.",
                    "label": 0
                },
                {
                    "sent": "Abit like what I showed you in the example right for each similar geometric for its enlarging metrics we will compare, you know, our candidate against drugs that are already known to interact.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "There's a number of similarity metrics that we have is much higher than what other system had.",
                    "label": 0
                },
                {
                    "sent": "As a result, we have a much larger number of features and that poses a potential problem of overfitting.",
                    "label": 0
                },
                {
                    "sent": "For machine learning, approach is very important to address that using L2 regularization.",
                    "label": 0
                },
                {
                    "sent": "So instead of building 1 model we actually build.",
                    "label": 0
                },
                {
                    "sent": "Up to close to 8 models with different regularization parameter through validation cross validation, we get the best regression regularization factor.",
                    "label": 0
                },
                {
                    "sent": "We also get the best threshold right and at the end we can use that model to make our predictions.",
                    "label": 0
                },
                {
                    "sent": "So that's kind of the standard pipeline that we use, and you could ask why logistic regression.",
                    "label": 0
                },
                {
                    "sent": "We actually we actually tested many order and models.",
                    "label": 0
                },
                {
                    "sent": "You just turned out that logistic regression is the one that produced the best performance in terms of quality of our predictions.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now I'm going to describe briefly some of the measures that we used to compare drugs.",
                    "label": 0
                },
                {
                    "sent": "The first one is the chemical putting into a term incorrect term profile based in large measure.",
                    "label": 0
                },
                {
                    "sent": "So what we call CPI profile for drug, it's essentially a vector that measure how well your drugs had binds against about 600 human proteins, right?",
                    "label": 0
                },
                {
                    "sent": "And we compare these drugs based on how well these you know.",
                    "label": 0
                },
                {
                    "sent": "We compared to drugs based on the cosine, you know.",
                    "label": 0
                },
                {
                    "sent": "So mean, center cosine of the CPI profile vector.",
                    "label": 0
                },
                {
                    "sent": "It's essentially you're kind of computing the Pearson correlation between the two vectors.",
                    "label": 0
                },
                {
                    "sent": "Another important similarity measure is the mechanism of action based in large measure, you saw that in the example we get for each drug we get information about its mechanism of action from a source which is part of your melesko NDF RT and conceptually for each drug we then have a vector of all its mechanism of action.",
                    "label": 0
                },
                {
                    "sent": "It's important to discount frequently occurring mechanism of action mechanism.",
                    "label": 0
                },
                {
                    "sent": "Action data just too generic to popular.",
                    "label": 0
                },
                {
                    "sent": "We use the IDF inverse document frequency to you know to discount them.",
                    "label": 0
                },
                {
                    "sent": "So and at the end we we perform the IDF adjusted cosine similarity matrix as our signature value.",
                    "label": 0
                },
                {
                    "sent": "So same approach is used for pathways so we get from another source called CTD for each drug we have the list of biological pathways in which the drug is involved or at least bearish pathway.",
                    "label": 0
                },
                {
                    "sent": "That's a drug.",
                    "label": 0
                },
                {
                    "sent": "May I disrupt or.",
                    "label": 0
                },
                {
                    "sent": "Interfere with right?",
                    "label": 0
                },
                {
                    "sent": "And then you compare this drug based on on on these basket pathways vectors and again using IDF adjust the cosine similarity measures.",
                    "label": 1
                },
                {
                    "sent": "We have many more similarity measure.",
                    "label": 1
                },
                {
                    "sent": "I won't go into more detail just to say that another interesting one is to compare drugs based on the similarity of the of the physiological effect that they have in the body.",
                    "label": 0
                },
                {
                    "sent": "Another interesting one is comparing comparison of drugs based and then known side effect and you can have more.",
                    "label": 1
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Detail in the paper.",
                    "label": 0
                },
                {
                    "sent": "Now let me briefly describe how we build.",
                    "label": 0
                },
                {
                    "sent": "Once we have all these similarity measure measures 13 in the paper 20.",
                    "label": 0
                },
                {
                    "sent": "Currently, how we go from there?",
                    "label": 0
                },
                {
                    "sent": "How we go from there to actually building?",
                    "label": 0
                },
                {
                    "sent": "You know, the set of features.",
                    "label": 0
                },
                {
                    "sent": "So, given a drug you know probably look like that we have our set of non drug similarity.",
                    "label": 0
                },
                {
                    "sent": "So we pick two similarity S1 and S2.",
                    "label": 0
                },
                {
                    "sent": "So we we compare our our candidate against each non drugs and obviously we still use how many means to combine the two score.",
                    "label": 0
                },
                {
                    "sent": "Here we had zero, 44 had 0.80 zero point 6 at the end.",
                    "label": 0
                },
                {
                    "sent": "The first feature that we use is the maximum value that we get here is 0.8 that's our first feature.",
                    "label": 0
                },
                {
                    "sent": "This actually what externally this standard feature using most system.",
                    "label": 0
                },
                {
                    "sent": "It gives you an idea of it tells you that there is a drug that is very similar to yours.",
                    "label": 0
                },
                {
                    "sent": "Your candidate right, but it just provides a limited view of all that distribution.",
                    "label": 1
                },
                {
                    "sent": "So really what we want to do is add additional calibration feature to really summarize the distribution.",
                    "label": 0
                },
                {
                    "sent": "So we use.",
                    "label": 0
                },
                {
                    "sent": "In addition we use mean standard deviation and this call for that Max value, which essentially tells us how far from the mean that Max value.",
                    "label": 0
                },
                {
                    "sent": "He's so it tell us whether you know that maximum value that we have, it's really outlier or it's really close to the mean.",
                    "label": 0
                },
                {
                    "sent": "The average I'm not going to go.",
                    "label": 0
                },
                {
                    "sent": "Another important similarity measure that we use here is these calibration and metrics.",
                    "label": 0
                },
                {
                    "sent": "So if you look at all the measure that we have now, they're actually comparing our candidate drugs against drugs that are known to interact.",
                    "label": 0
                },
                {
                    "sent": "But it could be the fact that you found a pair of drugs that is very similar to.",
                    "label": 0
                },
                {
                    "sent": "Are these drugs, but at the same time that pair of drawings also seem not to just all drugs, right?",
                    "label": 0
                },
                {
                    "sent": "So it's very important to also have a metrics that tell us what the average you know similarity of your candidate against all drugs, whether or not they are known to interact, and that's what that last feature does.",
                    "label": 1
                },
                {
                    "sent": "So at the end we end up with, you know, this number of features.",
                    "label": 0
                },
                {
                    "sent": "That's why it's very important to to care about, you know, overfitting and regularization.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So I'm not going to go in detail of how we make our you know how we find these lower bound for the drug drug interaction prevalence.",
                    "label": 0
                },
                {
                    "sent": "But you can see the detail in the paper in a nutshell, we were able to estimate that in reality you know the proof, the fraction of drug drug interaction in the set of all drugs is somewhere between 10 and 30%.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now evaluation, we did two experiments to evaluate the quality of our prediction.",
                    "label": 0
                },
                {
                    "sent": "The first is kind of a retrospective analysis where we try to see the extent to which our system is able to make correct prediction, but yet unknown prediction.",
                    "label": 0
                },
                {
                    "sent": "So in order to do that, we run our system using only, you know, drugs, drugs, pair that were known as of 2011.",
                    "label": 1
                },
                {
                    "sent": "So we were trying to simulate what could we have discovered if we had run our system in 2011.",
                    "label": 0
                },
                {
                    "sent": "What is the fraction of new drug interaction that we could have a discover back in 2011?",
                    "label": 0
                },
                {
                    "sent": "And the answer is that we can actually discover up to 28% drug interaction and we do a much better when we use the calibration feature that we introduce.",
                    "label": 0
                },
                {
                    "sent": "So this gives us an idea about the coverage of our system, right?",
                    "label": 0
                },
                {
                    "sent": "We still need to correct precision or you know, the first positive rate, right?",
                    "label": 0
                },
                {
                    "sent": "So I.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "I'm running out of time, so we did the standard 10 fold cross validation experiment to measure our F score and but also the area under the curve and we.",
                    "label": 1
                },
                {
                    "sent": "We evaluate how this matrix, if you know, evolved as we change the fraction of positive and negative example and what you can see from this curve is that is really important to actually consider relatively low performance.",
                    "label": 0
                },
                {
                    "sent": "So in a nutshell, let me just summarize the result here so that curve that you see here the dotted black line.",
                    "label": 0
                },
                {
                    "sent": "This is essentially the baseline that's the state of the art system really without using our our calibration feature and using a 5050%.",
                    "label": 1
                },
                {
                    "sent": "Balance training data set.",
                    "label": 0
                },
                {
                    "sent": "So what you can see is that is clearly underperformed our system when we use unbalanced data and when we use our collaboration features.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And maybe you have one second without probably step here and ask for questions.",
                    "label": 0
                },
                {
                    "sent": "And if I don't have enough question, maybe I can give you a demo quickly.",
                    "label": 0
                }
            ]
        }
    }
}